Drugs / BGB-B3227
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06540066 | Sep 2024 → Jan 2026 | cancer of unknown primary site, metastatic malignant neoplasm | BeiGene | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-B3227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06540066 ↗ |
| Route | Intravenous | “Administered intravenously.” NCT06540066 ↗ |